Charles River’s CDMO revenue rise; Catalent lays off 300 staffers; Biogen’s idle capacity

Charles Riv­er’s over­all man­u­fac­tur­ing busi­ness saw a 9.5% de­crease in rev­enue in the last quar­ter of 2023 with $191.9 mil­lion, ver­sus $212.1 mil­lion in the same quar­ter the year pri­or. Its 2023 rev­enue al­so de­creased to $721.1 mil­lion, down from 2022’s $789.6 mil­lion.

But the com­pa­ny is still op­ti­mistic for its man­u­fac­tur­ing busi­ness, which is made up of its CD­MO, mi­cro­bial so­lu­tions and bi­o­log­ics test­ing seg­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.